JORNAY PM
Attention-Deficit/Hyperactivity Disorder (ADHD)
Approved/CommercialMarketed
Key Facts
Indication
Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase
Approved/Commercial
Status
Marketed
Company
About Collegium Pharmaceutical
Collegium Pharmaceutical is a U.S.-based biopharmaceutical company with a mission to improve the lives of people living with serious medical conditions. The company has built a commercial portfolio centered on responsible pain management and has recently expanded into ADHD treatment through strategic acquisitions, such as AZSTARYS®. Led by a seasoned executive team with deep industry experience, Collegium is focused on growing its diversified portfolio and maintaining a strong commitment to corporate social responsibility and community impact.
View full company profileTherapeutic Areas
Other Attention-Deficit/Hyperactivity Disorder (ADHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Qelbree® (viloxazine ER) | Supernus Pharmaceuticals | Approved/Commercial |
| AZSTARYS | Collegium Pharmaceutical | Approved/Commercial |